The US drug agency has approved the corona vaccine from the US corporation Johnson & Johnson. The vaccine offers several advantages.
After the vaccine from Johnson & Johnson in the USA was admitted, is now also moving Admission in Europe closer. On March 11, the European Medicines Agency (EMA) wants to decide on the recommendation of the US manufacturer’s vaccine.
The responsible committee for human medicine will then meet for an extraordinary meeting, said the EMA With. The experts are expected to give the green light for approval in the EU. The EU Commission then has to give its formal approval – that could happen on the same day.
Johnson & Johnson received emergency approval in the United States
In the US it had the national Drug Agency FDA the mean of Johnson & Johnson an emergency license issued. Lower hurdles apply to this form of approval. The vaccine is approved for use from the age of 18. The company plans to have 20 million cans ready by the end of March, the first of which will start next week. By the end of June there should be 100 million cans.
The manufacturer Johnson & Johnson is best known in Germany for its cosmetic and hygiene products. The group also has its own pharmaceutical division. The vaccine that has now been approved is the third approved in the USA alongside the funds from Biontech / Pfizer and Moderna. The latter have already given more than 66 million injections across the US.
Coronavirus – The most important news at a glance
Johnson & Johnson has several advantages
The Swedish-British vaccine Astrazeneca, which is injected in Europe and in many other countries, has not yet been used in the United States. Like Astrazeneca, Johnson & Johnson is a vector vaccine. It is much easier to use than many other corona vaccines.
So he can at plus temperatures in the refrigerator and does not have to be frozen like those from Pfizer / Biontech. According to Johnson & Johnson, the product can be kept for at least three months at temperatures between two and eight degrees.
Another advantage over all current competing products: A single dose is enough for the full protective effect unfolds. The other vaccines that are currently used around the world, on the other hand, require two syringes.
US President Biden is extremely enthusiastic
US President Joe Biden spoke of “exciting news for all Americans and an encouraging development in our endeavors to end the crisis”. Biden called on US citizens to remain cautious despite the hope of the new vaccine: “We cannot give the all-clear now or assume that victory is inevitable,” he said.
At the end of January, Johnson & Johnson announced an interim result of its Phase III study with around 44,000 subjects, according to which the vaccine offers 66 percent protection against moderate or severe Covid-19 disease courses four weeks after administration. The effectiveness against serious illnesses was given significantly higher.
Corona vaccination – More about the vaccines:
Studies have shown that it is highly effective against serious diseases
According to this, the agent prevented serious illnesses by 85.9 percent in a large clinical study in the USA. In studies in South Africa and Brazil, where highly contagious variants of the pathogen are currently predominant, the effectiveness was somewhat lower, but still provided similarly strong protection against serious diseases.
The percentages mean that it is in the vaccinated volunteer group there were correspondingly fewer cases than in the placebo group. Study results show that some of the competing products are more effective.
Data on the duration of vaccination protection are not yet available, said the FDA. There is also no reliable information on whether vaccinated people transmit the SARS-CoV-2 virus. In early February, Johnson & Johnson applied for emergency approval from the FDA. The application followed in mid-February EU Medicines Agency EMA.
European Union has ordered 200 million cans from Johnson & Johnson
The EMA said it would be the vaccine from the Belgian Johnson & Johnson subsidiary Janssen-Cilag International NV examine in an expedited procedure. The EU Commission has ordered vaccination doses for 200 million people from Johnson & Johnson. She also has an option for another 200 million cans.
Other countries are also showing interest in the new vaccine: it was the only country before the USA that had Gulf state of Bahrain With its 1.6 million inhabitants, the active ingredient was granted emergency approval by Johnson & Johnson at the end of February.
Coronavirus – The most important news at a glance
The largest single batch is reserved for developing countries
Great Britain, which is no longer part of the EU, has ordered 30 million cans. Canada has secured 38 million cans. By far the largest single quantity of 500 million cans is for the international Covax vaccine platform reserved, through which vaccines for developing countries are procured and financed.
The new vaccine uses a so-called adenovirus as a vector. This usually triggers a common cold, but has been modified to prevent it from multiplying. On the vector genetic instructions are transmitted to the cells to produce a specific protein of the coronavirus. This prepares the immune system to fight the real coronavirus.
Corona – More information on the topic